Transcriptional transactivator peptide modified lidocaine-loaded nanoparticulate drug delivery system for topical anesthetic therapy

Yan Wang,Shenhui Wang,Pengcai Shi
DOI: https://doi.org/10.3109/10717544.2016.1160459
IF: 6.819
2016-04-05
Drug Delivery
Abstract:PURPOSE: For the topical anesthetic, transcriptional transactivator peptide (TAT) modified lidocaine (LID) loaded nanostructured lipid carriers (TAT-NLCs-LID) were prepared and then used for improving transdermal delivery of local anesthetic drug.METHODS: In this study, TAT was conjugated with Distearoyl phosphatidylethanolamine-(polyethylene glycol)<sub>2000</sub>-maleimide (DSPE-PEG<sub>2000</sub>-Mal) to obtain TAT-PEG<sub>2000</sub>-DSPE. TAT-NLCs-LID were successfully prepared and characterized by determination of their particle size, morphology, drug encapsulation efficiency and in vitro drug release behavior. The skin permeation of LID-LNPs was examined using a Franz diffusion cell mounted with depilated mouse skin in vitro and in vivo anesthesia effect was evaluated on mice.RESULTS: The results showed that TAT-NLCs-LID have substantially small mean diameter (157.9 nm) and high encapsulation efficiency (81.8%). From the in vitro skin permeation results, transdermal flux of TAT-NLCs-LID was about several times higher than that of LID solution and NLCs-LID. In vivo anesthesia effect evaluation illustrated that TAT-NLCs-LID can enhance the transdermal delivery of LID by reducing the pain threshold in mice.CONCLUSION: These results indicate that the novel TAT containing drug delivery system is very useful for overcoming the barrier function of the skin and could deliver anesthetic through the skin. TAT-NLCs-LID could function as promising topical anesthetic system.
pharmacology & pharmacy
What problem does this paper attempt to address?